Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2020;31(2):239-41
Article Links
Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
Dimitrios Daoussis1, Konstantinos Melissaropoulos2, Theodoros Dimitroulas3, Haralambos Andreadis4, Athina Christopoulou5, George Douganiotis4, Thomas Makatsoris6, Angelos Koutras6, Panagiotis Georgiou2, Haralabos Kalofonos6
Authors Information

1.Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece

2. Department of Rheumatology, Agios Andreas Hospital, Patras, Greece

3. 4th Department of Internal Medicine Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

4. 3rd Department of Clinical Oncology, Theageneio Cancer Hospital, Thessaloniki, Greece

5. Oncology/Chemotherapy Unit, Agios Andreas Hospital, Patras, Greece

6. Department of Oncology, Patras University Hospital, University of Patras Medical School, Patras, Greece

Keywords: immune checkpoint inhibitors, musculoskeletal, arthritis, rheumatic, cancer immunotherapy, anti-PD-1, anti-CTLA4
References
  1. Tivol EA, Borriello F, Nicola Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4. Immunity 1995 Nov;3(5):541-7.
  2. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999 Aug;11(2):141-51.
  3. Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 2018 Jan 1;29(1):71-83.
  4. Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018 Jan 11;378(2):158-68.
  5. Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf 2018;13(3):150-64.
  6. Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018 Mar 1;77(3):393-8.
  7. Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García del Muro X, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 2018 Oct;17(10):1040-5.
  8. Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, et al. MRI study of immune checkpoint inhibitor–induced musculoskeletal manifestations. Myofasciitis is the prominent imaging finding. Rheumatol 2019;In press.
  9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009 Jan 1;45(2):228-47.
  10. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 2018 Feb 1;128(2):715-20.